Home > Cardiology > AHA 2020 > Miscellaneous > Dobutamine versus milrinone in cardiogenic shock

Dobutamine versus milrinone in cardiogenic shock

AHA 2020
Capital Do-Re-Mi

A randomised clinical trial compared 2 inotropic agents that are often used to treat cardiogenic shock: milrinone and dobutamine. The results showed no difference in the primary composite outcome or in important individual components of the primary outcome [1]. Thus, the authors concluded that the choice might be based on physician comfort, cost, and individual response to therapy.

So far, little evidence has been available to guide physicians in their choice of inotropic agents for cardiogenic shock in clinical practice. Therefore, the Capital Do-Re-Mi trial (NCT03207165) was set up. It was designed as a double-blind, randomised controlled trial, including 192 cardiogenic shock patients with class B to E shock according to the classification of the Society for Cardiovascular Angiography and Interventions (SCAI). Participants were assigned 1:1 to milrinone or dobut...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on